A Survey of Measures Used for the Prevention of Postoperative
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Prevalence of Self-Medication of Antibiotics Among People In
International Journal of Pharmacy Teaching & Practices 2013, Vol.4, Issue 1, 504-510. Prevalence of self-medication of antibiotics among people in Bangladesh Nishat Chowdhury*, Mohammad Rashedul Islam, Md. Mehedi Hasan, Md. Mahmudur Rouf *Department of Pharmacy, State University of Bangladesh, Dhanmondi, Dhaka, Bangladesh Introduction Research Article Widespread and inappropriate use of antibiotics increases health care costs (1) and contributes to Please cite this paper as: Nishat Chowdhury*, Mohammad Rashedul Islam, Md. Mehedi Hasan, Md. Mahmudur Rouf. Prevalence of self- antibiotic resistance (2)。 Antimicrobial medication medication of antibiotics among people in Bangladesh . IJPTP, 2013, management in Bangladesh has been highlighted by 4(1), 504-510. previous studies as an area for improvement (3). Corresponding Author: There is already enough evidence of growing resistance to antimicrobials in this country resulting Nishat Chowdhury, from misuse (4-6). Previous study showed that Department of Pharmacy, State University of Bangladesh, antimicrobials are widely available (18% incidents) in Dhanmondi, Dhaka, Bangladesh the home medicine cabinets of the Dhaka City Telephone -88028612992, population (7). Since there is no prescription-only Email: [email protected] drug in Bangladesh, people can purchase drugs like sedatives, antimicrobials without prescription even in the remote parts of the country (8-9). The relative Abstract lack of data on the morbidity and mortality attributable to antibiotic resistance, including the This study attempts to investigate the prevalence of self- economic impact on individuals as well as on health medication of antibiotics among people in Bangladesh.This care and societies, may explain the weak reaction study was conducted in six districts of Bangladesh (Dhaka, from politicians, public health workers, and Munshiganj, Kishoreganj, Chittagong, Chandpur, Kushtia) by consumers to this threat to public health (10). -
Diagnosing Dry Eye
MEDICAL ED NG UC UI AT A CONTINUING TIN IO CON N MEDICAL EDUCATION PUBLICATION CME ISSUE 14 Diagnosing Dry Eye ERIC D. DONNENFELD, MD Dry eye a ects tens of millions of patients and is among the most common reasons for eye care provider visits. Knowing what to look for, how, and in whom (hint: everyone) can help stem the tide of this quiet epidemic. Th e exact prevalence of dry eye is diffi cult to ascertain, for several reasons, including the absence of a single test (or universally accepted sequence of tests) for its diagnosis, and the fact that patient-reported symptoms are oft en poorly con- cordant with objective assessments.1 Estimates based on cohort studies suggest that about 5% to 35% of adults worldwide have dry eye, a rate that is expected to rise in the upcoming decades FIGURE 1 Lid margin with inspissated meibomian glands and pasty as common risk factors, including advanced age, increase.2,3 secretions indicative of MGD. Sometimes even higher estimates are cited, as dry eye symp- toms are oft en camoufl aged by other ocular surface condi- tions such as allergic conjunctivitis, surgery, and contact lens CATEGORIES AND MECHANISMS discomfort; in addition, many patients—up to 60% of those Dry eye is generally divided into two main categories based with objective evidence of dry eye—are pre-symptomatic.3 on the underlying cause: aqueous defi cient and evaporative.4 Th e landmark 2007 International Dry Eye Workshop Aqueous defi ciency describes inadequate tear production by (DEWS) report off ered the fi rst thorough expert review around the lacrimal glands. -
Role of Intracameral Dexamethasone in Preventing Immediate Postoperative Anterior Uveitis in Paediatric Cataract Extraction
ORIGINAL ARTICLE Role of Intracameral Dexamethasone in Preventing Immediate Postoperative Anterior Uveitis in Paediatric Cataract Extraction CHAUDARY NASIR AHMAD, ASAD ASLAM KHAN, ZAHID SIDDIQUE, SHAKIL AHMED ABSTRACT Objective: Paediatric cataract surgery can result in several complications like post operative inflammation. Topical steroids are relied upon as mainstay of treatment and prevention, adjuvant periocular and systemic steroids may be required to control the inflammation. The purpose of study was to evaluate the role of intracameral dexamethasone in preventing immediate postoperative anterior uveitis in paediatric cataract extraction. Methods: This was comparative study done at institute of Ophthalmology Mayo Hospital Lahore. Sixty patients were selected and divided into two equal groups. Group I were given routinely subconjuctival injection of gentamycin 20 mg and dexamethasone 2 mg while patients in group II were given subconjuctival injection of gentamycin 20 mg and intracameral dexamethasone 0.4 mg (0.1ml). Evaluation was done on 1st and 3rd postoperative day and on first follow up visit. Examination of children was done with help of slit lamp for cells, flare or any other sign of inflammation. In case of non cooperative children examination was done with microscope under sedation/general anesthesia for fibrinous reaction, exudative membrane, posterior synechiae and red reflex. Results: There were total of sixty patients age below 12 years divided into two equal groups, 43 were males and 17were females. Group I was given routinely subconjuctival injection of dexamethasone, while group II patients were given intracameral injection of dexamethasone. Group II patients showed better results than that of group I. Conclusion: Intracameral injection of dexamethasone was found superior to subconjuctival injection of dexamethasone in preventing immediate postoperative anterior uveitis. -
Intracameral Therapeutics for Cataract Surgery
s THE LITERATURE INTRACAMERAL THERAPEUTICS FOR CATARACT SURGERY Closing in on no-drop surgery. BY MARK A. KONTOS, MD; AND KENDALL E. DONALDSON, MD, MS DEXAMETHASONE INTRACAMERAL ninety-four patients scheduled for Anterior chamber cell clearing at DRUG-DELIVERY SUSPENSION FOR cataract surgery at 27 sites were day 8 was achieved in 25% of eyes INFLAMMATION ASSOCIATED WITH randomly assigned to three groups. in group 1, 63% in group 2, and CATARACT SURGERY: A RANDOMIZED, Group 1 received a 5-µL injection of 66% in group 3 (P > .001). Anterior PLACEBO-CONTROLLED PHASE III TRIAL placebo. Groups 2 and 3, respectively, chamber flare clearing at day 8 was received a 5-µL injection of 342 µg or achieved in 63.8% of eyes in group 1, Donnenfeld E, Holland E1 517 µg dexamethasone drug delivery 92.4% in group 2, and 89.1% in group suspension into the anterior chamber 3 (P > .001). Adverse events were ABSTRACT SUMMARY at the conclusion of cataract surgery. similar among the three groups with In this randomized, double-masked, Patients were observed for 90 days no serious adverse events reported up placebo-controlled study, inves- after surgery. to postoperative day 90. tigators sought to determine the The primary outcome measure safety and efficacy of dexamethasone was anterior chamber cell clearing DISCUSSION intraocular suspension 9% (Dexycu, at postoperative day 8. Secondary The appropriate postoperative EyePoint Pharmaceuticals) for measures were anterior chamber flare medical regimen for cataract surgery intracameral administration in and anterior chamber cell plus flare remains a hotly debated subject. The two dosages in patients undergoing clearing in the study eyes. -
Consideration of Antibacterial Medicines As Part Of
Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1. -
Intracameral Antibiotics for the Prevention of Endophthalmitis Post-Cataract Surgery: Review of Clinical and Cost-Effectiveness and Guidelines
Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé Rapid Response Report: Peer-Reviewed Summary with Critical Appraisal CADTH Intracameral Antibiotics for the Prevention of Endophthalmitis Post-Cataract Surgery: Review of Clinical and Cost-Effectiveness and Guidelines October 2010 Supporting Informed Decisions Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Publications can be requested from: CADTH 600-865 Carling Avenue Ottawa ON Canada K1S 5S8 Tel.: 613-226-2553 Fax: 613-226-5392 Email: [email protected] or downloaded from CADTH’s website: http://www.cadth.ca Cite as: Ndegwa S, Cimon K, Severn M. Intracameral Antibiotics for the Prevention of Endophthalmitis Post-Cataract Surgery: Review of Clinical and Cost-Effectiveness and Guideline [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010 (Rapid Response Report: Peer-Reviewed Summary with Critical Appraisal). [cited 2010-10-07]. Available from: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/2683 Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Prince Edward Island, Saskatchewan, and Yukon. The Canadian Agency for Drugs and Technologies in Health takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada, or any provincial or territorial government. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CADTH. -
How to Address Dry Eye in the Challenging Cornea Understand Dry Eye’S Various Factors and Causes to Get Ahead of the Treatment Curve
MARCH 2021 | 16 Ocular Surface Disease How to address dry eye in the challenging cornea Understand dry eye’s various factors and causes to get ahead of the treatment curve By Seema Nanda, OD Levels of severity y eyes are getting watery after log- For everyone who has been stuck at home binge ging off my tenth Zoom meeting watching Netflix, you know exactly what it feels this week, which makes me think like to have dry eyes. For the sake of simplic- of the others Zooming away and ity, dry eye symptoms can be reduced to the Mexperiencing dry eye symptoms. As an optom- levels of mild, moderate, or severe. etrist who sees corneal calamities on a contin- For mild cases, preservative-free artificial ual basis, it can become a challenge to treat. tears, such as Refresh Relieva (Allergan) and At first, clinicians may Retaine MGD (OCuSOFT), are excellent options. diagnose dry eye dis- Refresh Relieva contains an inactive ingredi- ease (DED) by observing ent, hyaluronic acid, that I have personally and simple superficial punc- anecdotally found to soothe the corneal sur- tate keratitis at the slit face. For moderate conditions, twice-daily use of lamp. However, compli- Retaine MGD drops combined with a clinically cations may ensue, such validated nutritional supplement can provide as recurrent epithelial ero- relief to the deficient lipid profile. For severe sions or persistent epithe- symptoms, additional therapies should be imple- SEEMA NANDA, lial defects, causing more mented to maintain the corneal integrity. OD, is in practice in Houston, Texas. problems. These chal- lenges could lead to neu- Use a supplement rotrophic ulcers and become even more difficult A supplement such as HydroEye (ScienceBased to handle. -
Management of Acute Corneal Hydrops Secondary to Keratoconus by Descemetopexy Using Intracameral
NUJHS Vol. I, No.4, December 2011, ISSN 2249-7110 Nitte University Journal of Health Science Case Report MANAGEMENT OF ACUTE CORNEAL HYDROPS SECONDARY TO KERATOCONUS BY DESCEMETOPEXY USING INTRACAMERAL PERFLUOROPROPANE (C3F8) – A CASE REPORT Vijay Pai 1, Jayaram Shetty 2, Hrishikesh Amin 3, S. Bhat 4, Divya Lakshmi 5 1 Professor, 2 Prof.& Head, 3 Professor, 4 Assoc. Professor, 5 Sr. Resident, Dept. of Ophthalmology, K.S. Hegde Medical Academy, Deralakatte, Mangalore - 575 018. Correspondence: Vijay Pai, Professor, Dept. of Ophthalmology, K.S. Hegde Medical Academy, Deralakatte, Mangalore – 575018. E-mail : [email protected], [email protected] Abstract : Keratoconus is a clinical term used to describe bilateral non-inflammatory corneal ectasia in its axial part due to which cornea assumes a conical shape1. The onset of keratoconus is generally at the age of puberty, and progresses over a period of 10-20 years2,3. The treatment of Keratoconus is rarely an emergency, with the exception of corneal hydrops resulting from rupture of the Descemet's membrane. This may be the common mode of presentation in patients with associated developmental delay, probably related to habitual ocular massage4,5. Keywords : Keratoconus, acute hydrops, descemetopexy, C3F8 Case Report : Descemetopexy under intravenous sedation, after A 21 year old girl presented to the cornea services of Justice obtaining an informed consent. Preoperatively, the pupil K.S. Hegde Charitable Hospital, Mangalore with complaints was constricted using 2% Pilocarpine eye drops, 1 drop of sudden decrease in vision in the right eye since one every 15 min, 1 hour prior to the surgery, not only to avoid week. -
2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5 -
Cefotaxime: Rate of Bacterial Killing and Interactions with Serum and Leukocyte Activity
ACTA M~DICA PORTUGUESA 1983; 4: 167-171 ORIGINAL CEFOTAXIME: RATE OF BACTERIAL KILLING AND INTERACTIONS WITH SERUM AND LEUKOCYTE ACTIVITY GIULIANA GIALDRONI GRASSI, PATRIZIA MANGIAROTTI, ANNA FIETTA Chair of Chemotherapy. Istituto Forlanini. University of Pavia. Italy SUMMARY Cefotaxime (HR 756) was compared with cefazolin and cephaloridine with regard to the rate of bacterial killing and to the influence on the bactericidal activity of human serum and polyrnorphonuclear leukocytes. At concentrations equal to 1-2 x MIC cefotaxime showed a more rapid and complete bactericidal activity on E. coil K 12 than cephaloridine and cefazolin. In presence of the latters in fact, bacterial regrowth was observed after 24 hours. On S. aureus a complete killing activity of cefotaxime appeared at concentrations of 8 x MIC. A synergism seemed to exist between the complement dependent bactericidal activity of normal human serum and cephalosporins. E. coil K 12 (a rough strain) was killed by the combi nation of human serum and both cefotaxime and cefazolin at concentrations that were not bactericidal by themselves. Cephaloridine on the contrary showed an additive activity with normal human serum. Finally evidence that cefotaxime enhanced the bactericidal activity of human polymorphonuclear leukocytes against S. faecaiis, is reported. RESUMO Cefotaxirna: Poder Bactericida e Interaccao corn a Actividade Leucocitãria e do Soro. Cornparou-se o poder bactericida e a interferência da cefotaxima (HR 756) na actividade bactericida dos leucocitos polimorfonucleares e do soro corn os parametros equivalentes referentes a cefazolina e a cefaloridina. A concentracOes equivalentes a 1-2 vezes a concentracao Inibitória Minima (CIM) a cefotaxima revelou uma accAo bactericida mais rápida e completa sobre o E. -
Analysis of Cephalosporins on a Polar Endcapped C18 3 Um Particle
Application Note 20672 Note Application Analysis of Cephalosporins on a Polar Endcapped C18 3 µm Particle Column Valeria Barattini, Thermo Fisher Scientific, Runcorn, Cheshire, UK Key Words Syncronis, aQ, cephalosporins, polar endcapping, antibiotics Abstract The analysis of species containing polar groups using reversed phase HPLC can be challenging. The polar groups present on the analytes can result in secondary interactions with silanols on the silica surface. Furthermore, the overall polarity of the molecule sometimes calls for the use of mobile phases with very high aqueous content to ensure the analyte solubility, retention and elution, at the expense of stationary phase stability. In this application note we demonstrate the analysis of a mix of four analytes from the cephalosporin antibiotics family on a Thermo Scientific™ Syncronis™ aQ 3 µm particle column. The analysis yields excellent peak shape and resolution in short run times, as well as outstanding reproducibility. Introduction One of the key goals for the chromatographer is to achieve a consistent, reproducible separation. The selection of a highly reproducible HPLC column is essential if this goal is to be attained. The Syncronis column range has been engineered to provide exceptional A group of four cephalosporins, listed in Figure 2, was reproducibility due to its highly pure, high surface area chosen to be separated using a Syncronis aQ column with silica, dense bonding and double endcapping, all a 3 µm particle. Two of the components (cephalexin and controlled and characterized through the use of rigorous cefradin) differ only in the presence of a phenyl group in testing. The aQ phase endcapping group has been further chephalexin compared to a 1,4-cyclohexadiene in optimized to provide a controlled interaction mechanism cefradine. -
European Surveillance of Healthcare-Associated Infections in Intensive Care Units
TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................